Table 2.
Changes in clinical characteristics in the 16 patients who received oral semaglutide for 24 weeks
| Semaglutide therapy | |||||
|---|---|---|---|---|---|
| Baseline | 12 weeks | * P value | 24 weeks | * P value | |
| Body weight (kg) | 74.4 (72.0–86.9) | 72.5 (70.8–85.0) | <0.001 | 72.6 (67.8–83.5) | <0.001 |
| BMI (kg/m2) | 29.6 (27.4–33.7) | 28.7 (26.7–31.8) | <0.001 | 28.4 (25.4–31.2) | <0.001 |
| Platelets (×103/μL) | 231 (183–285) | 249 (206–280) | <0.05 | 238 (222–295) | <0.01 |
| AST (U/L) | 40 (37–50) | 32 (24–37) | <0.001 | 30 (22–34) | <0.001 |
| ALT (U/L) | 67 (44–81) | 42 (32–47) | < 0.01 | 34 (27–49) | <0.01 |
| γ‐GTP (U/L) | 66 (55–114) | 44 (37–72) | <0.001 | 41 (29–60) | <0.001 |
| eGFR (mL/min/1.73m2) | 67 (61–94) | 71 (60–88) | 0.44 | 72 (65–87) | 0.57 |
| Uric acid (mg/dL) | 5.3 (5.0–6.9) | 5.4 (4.8–6.4) | <0.05 | 5.9 (5.2–7.0) | 0.92 |
| LDL cholesterol (mg/dL) | 101 (84–141) | 80 (77–129) | <0.01 | 125 (75–136) | 0.11 |
| HDL cholesterol (mg/dL) | 45 (43–51) | 43 (39–50) | <0.05 | 47 (38–50) | 0.44 |
| Triglyceride (mg/dL) | 175 (122–246) | 150 (110–207) | 0.10 | 128 (113–200) | <0.05 |
| Plasma glucose (mg/dL) | 123 (119–138) | 102 (98–110) | <0.01 | 102 (93–106) | <0.01 |
| HbA1c (%) | 6.9 (6.6–7.3) | 6.0 (5.9–6.4) | <0.001 | 5.9 (5.6–6.1) | <0.001 |
| Insulin (μU/mL) | 19.8 (15.4–32.8) | 23.5 (14.4–45.3) | 0.15 | 15.6 (11.9–24.0) | <0.05 |
| HOMA‐IR | 6.6 (4.3–11.2) | 6.4 (4.2–11.4) | 0.96 | 4.3 (2.9–6.2) | <0.01 |
| Ferritin (ng/mL) | 135.2 (101.3–259.6) | — | — | 103.0 (56.3–235.2) | <0.01 |
| Type IV collagen 7 s (ng/mL) | 4.1 (3.6–5.7) | — | — | 3.5 (2.7–4.5) | <0.05 |
| WFA+‐M2BP (C.O.I) | 0.85 (0.68–1.12) | — | — | 0.69 (0.51–1.00) | 0.16 |
| FIB‐4 index | 1.42 (0.69–3.25) | — | — | 1.10 (0.53–2.03) | <0.01 |
| CAP (dB/m) | 344 (312–354) | — | — | 279 (251–334) | <0.01 |
| LSM (kPa) | 5.5 (5.1–16.0) | — | — | 6.5 (4.4–10.8) | 0.17 |
Data are presented as medians (interquartile ranges).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; eGFR, estimated glomerular filtration rate; FIB‐4, fibrosis‐4; HbA1c, hemoglobin A1c; HDL, high‐density lipoprotein; HOMA‐IR, homeostasis model assessment‐insulin resistance; LDL, low‐density lipoprotein; LSM, liver stiffness measurement; WFA+‐M2BP, Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein; γ‐GTP, gamma glutamyl transpeptidase.
*
Versus baseline.